Priority question for written answer P-000607/2024
to the Commission
Rule 138
Susanna Ceccardi (ID)

Subject: Clarifying whether medicinal products are exempt from the requirements introduced by new EU trade sanctions

On 19 December 2023, the Commission adopted its 12th package of sanctions against Russia[1], which added a number of new trade bans, including on intra-company provision of services and software.

For some sectors, the introduction of these new measures might prevent the sanctions from working as intended, potentially hampering established product flows and patient access to essential medicines.

Guaranteeing that all medicinal products and related activities remain exempt from all direct and indirect sanctions is paramount to ensuring that EU patients can continue to access appropriate treatment.

In the light of the above:

1. Can the Commission confirm that medicinal products still enjoy the same general exemption, and that they therefore do not have to abide by the new requirements concerning intra-company provision of services and software?

2. Is the Commission planning either to issue specific guidance on this topic or to reflect on it when issuing future sanctions packages?

Submitted:23.2.2024

[1] https://neighbourhood-enlargement.ec.europa.eu/news/eu-adopts-12th-package-sanctions-against-russia-its-continued-illegal-war-against-ukraine-2023-12-19_en.